CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-515-3185
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$59.50 million
Profitability
Miscellaneous
Employees137
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions
What is CytomX Therapeutics' stock symbol?
CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."
How were CytomX Therapeutics' earnings last quarter?
CytomX Therapeutics Inc (NASDAQ:CTMX) posted its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.22. The biotechnology company had revenue of $29.49 million for the quarter, compared to analysts' expectations of $13.59 million. CytomX Therapeutics had a negative net margin of 111.27% and a negative return on equity of 73.62%. View CytomX Therapeutics' Earnings History.
When is CytomX Therapeutics' next earnings date?
What price target have analysts set for CTMX?
8 Wall Street analysts have issued 12 month price targets for CytomX Therapeutics' stock. Their forecasts range from $13.24 to $34.00. On average, they expect CytomX Therapeutics' share price to reach $21.28 in the next twelve months. This suggests a possible upside of 92.1% from the stock's current price. View Analyst Price Targets for CytomX Therapeutics.
What is the consensus analysts' recommendation for CytomX Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytomX Therapeutics.
What are Wall Street analysts saying about CytomX Therapeutics stock?
Here are some recent quotes from research analysts about CytomX Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Overweight rating and 12-month price target of $21/share. CytomX stock currently trades at an EV of ~$100M ($8.80/sh cash), and the shares are down about 27% YTD (vs. +8.5% for NBI), triggered by updates at its R&D day earlier this year. We believe that the company’s lead early-stage clinical assets, based on modified antibodies, are partially de-risked and are highly discounted at the current valuation. For CX-2009, we think that evolving clinical updates in the next 6-12 months should alleviate investor concerns about its safety profile and that risk of potential clinical setback is overstated." (5/13/2019)
- 2. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (4/30/2019)
- 3. HC Wainwright analysts commented, "We utilize a probability of approval of 70% for we employ a 10% discount rate, and a 29% effective tax rate, yielding a total value of $1.6B, or a price per share of $34, assuming 47.6M shares outstanding and roughly $329M in cash and equivalents as of end-4Q19." (4/3/2019)
Has CytomX Therapeutics been receiving favorable news coverage?
Press coverage about CTMX stock has been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CytomX Therapeutics earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of CytomX Therapeutics' key competitors?
Some companies that are related to CytomX Therapeutics include Xencor (XNCR), Allakos (ALLK), AnaptysBio (ANAB), Akcea Therapeutics (AKCA), Arrowhead Pharmaceuticals (ARWR), Pacira Biosciences (PCRX), Enanta Pharmaceuticals (ENTA), Tricida (TCDA), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Nabriva Therapeutics (NBRV), Zogenix (ZGNX), Zai Lab (ZLAB), Prestige Consumer Healthcare (PBH) and Madrigal Pharmaceuticals (MDGL).
What other stocks do shareholders of CytomX Therapeutics own?
Who are CytomX Therapeutics' key executives?
CytomX Therapeutics' management team includes the folowing people:
- Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)
- Mr. Debanjan Ray, Sr. VP & CFO (Age 41)
- Dr. Rachel Wallach Humphrey, Sr. VP & Chief Medical Officer (Age 58)
- Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)
- Dr. W. Michael Kavanaugh, Sr. VP, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63)
Who are CytomX Therapeutics' major shareholders?
CytomX Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.53%), Wellington Management Group LLP (7.28%), Perceptive Advisors LLC (7.00%), Perceptive Advisors LLC (7.00%), FMR LLC (4.72%) and Victory Capital Management Inc. (3.65%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Lloyd A Rowland, Rachel Humphrey, Robert I Tepper, Sean A Mccarthy and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics.
Which institutional investors are selling CytomX Therapeutics stock?
CTMX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FIL Ltd, Goldman Sachs Group Inc., Citigroup Inc., Man Group plc, Hamilton Lane Advisors LLC, Wells Fargo & Company MN and Renaissance Technologies LLC. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray and Sean A Mccarthy. View Insider Buying and Selling for CytomX Therapeutics.
Which institutional investors are buying CytomX Therapeutics stock?
CTMX stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Victory Capital Management Inc., Wellington Management Group LLP, First Manhattan Co., Perceptive Advisors LLC, Perceptive Advisors LLC, Spark Investment Management LLC and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for CytomX Therapeutics.
How do I buy shares of CytomX Therapeutics?
Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CytomX Therapeutics' stock price today?
One share of CTMX stock can currently be purchased for approximately $11.08.
How big of a company is CytomX Therapeutics?
CytomX Therapeutics has a market capitalization of $502.05 million and generates $59.50 million in revenue each year. The biotechnology company earns $-84,600,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. CytomX Therapeutics employs 137 workers across the globe.
What is CytomX Therapeutics' official website?
How can I contact CytomX Therapeutics?
CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]
MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
